Main Menu

This technology represents a groundbreaking approach to combating Ebola virus disease (EVD) by targeting key host cell signaling pathways implicated in the pathogenesis of the disease. Through innovative investigational strategies, the technology has identified specific kinase inhibitors that effectively reduce EVD progression in both cell culture and animal models. By focusing on pathways related to cell growth, survival, proliferation, and anti-apoptotic responses, this approach offers a novel therapeutic avenue for EVD treatment.

The N6 antibody represents a significant advancement in the quest for an effective HIV-1 vaccine. This novel antibody, isolated from B-cells of an HIV-1 infected individual, demonstrates potent and broad neutralizing activity against a wide range of HIV-1 isolates, including those resistant to other potent antibodies. N6 targets the CD4 binding site on the HIV envelope glycoprotein, particularly in the D-loop region, and exhibits higher potency than previously discovered antibodies like VRC01.

The technology pertains to the enhancement of HIV neutralizing antibodies, specifically VRC01, VRC07, and 10E8, which have been isolated and characterized for their potent antiviral activity. These antibodies have undergone specific mutations to improve their breadth and potency against a range of HIV strains. The aim is to extend their half-life, augment their in vivo effectiveness, and reduce immunogenicity.

The technology encompasses a novel set of fully human monoclonal antibodies targeting the spike (S) protein of coronaviruses, notably the SARS-CoV-2 virus responsible for COVID-19. These antibodies, derived from convalescent patients, offer potential for use in the diagnosis, monitoring, and treatment of coronavirus infections. This discovery includes a comprehensive library of antibody or antibody fragment candidates with high specificity for the coronavirus spike protein.

The live-attenuated Lassa virus vaccine, based on a recombinant Vesicular Stomatitis Virus (VSV) vector expressing the Lassa virus glycoprotein (GPC), represents a significant advancement in Lassa fever vaccination. This vaccine has demonstrated protective efficacy in animal models, showing promise for further development. Key advantages of this vaccine platform include its ability to replicate in the vaccinated individual, leading to a stronger immune response compared to non-replicating platforms.

The technology involves modifying HIV-1 envelope mosaic constructs to enhance the efficacy of HIV vaccines. These modifications target specific regions of the envelope protein, aiming to elicit antibodies similar to potent anti-HIV neutralizing antibodies naturally produced during infection. By replacing highly variable patches in the V1, V2, and V3 loops with defined sequences and eliminating immune-dominant epitopes, the modified constructs induce the production of quaternary antibodies.

The live-attenuated Nipah virus vaccines, based on recombinant Vesicular Stomatitis Virus (VSV) vectors, represent a groundbreaking approach to combating Nipah virus infections. These vaccines, expressing Nipah virus glycoprotein (G) or fusion protein (F), have demonstrated exceptional protective efficacy in animal models. Key advantages include their ability to replicate within the vaccinated individual, eliciting a robust immune response superior to non-replicating vaccine platforms.

The technology involves the development of novel PCSK9 immunogens that are specifically designed to eliminate sequence overlap with human proteins, thereby reducing potential self-reactivity and immunogenicity issues. By selectively grafting epitope residues from non-human PCSK9 or structurally similar sequences onto the epitope-scaffold, these immunogens can induce an immune response against the PCSK9 enzyme without triggering a significant reaction against the body’s own proteins.

The technology is a groundbreaking vaccine formulation developed through a meticulous analysis of tick salivary antigens crucial for parasitism. By examining gene expression in tick salivary glands across various life stages and comparing them with ticks feeding on naturally resistant hosts, key antigens were pinpointed. These antigens target molecules that inhibit host homeostatic responses and are predicted to be secreted toxins, making them ideal candidates for inducing immunity against tick parasitism.

This technology presents a novel strain of transgenic mice where the proto-oncogene c-Cbl (Casitas B-lineage lymphoma) has been engineered with loxP (locus of X-over P1) sites, commonly referred to as "floxed." This design enables the conditional knockout of the c-Cbl gene when the mice are crossed with strains that express the Cre recombinase enzyme. Cre recombinase is an enzyme that can specifically target loxP sites, excising the floxed gene only in the presence of Cre, thus allowing tissue-specific or temporal deletion of the target gene.